Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Summit Therapeu ADR (NQ: SMMT )

7.770 -0.240 (-3.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,164,944
Open 7.970
Bid (Size) 7.730 (3)
Ask (Size) 7.780 (6)
Prev. Close 8.010
Today's Range 7.660 - 8.180
52wk Range 1.520 - 11.25
Shares Outstanding 97,381,774
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Top Stocks Under $10: June 2024 Edition
While blue-chip stocks are great, it's also a good idea to invest in top stocks under $10 to help improve your portfolio's diversification. 
Via InvestorPlace
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
These high-flying stocks could have more room to run if analysts are right. 
Via The Motley Fool

Performance

YTD
+194.32%
+194.32%
1 Month
+225.10%
+225.10%
3 Month
+107.20%
+107.20%
6 Month
+181.52%
+181.52%
1 Year
+205.91%
+205.91%

More News

Read More
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Five Below Posts Weak Q1 Results, Joins Sprinklr, Dorian LPG And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why Summit Therapeutics Stock Is Trading 8% Higher Monday
Via Benzinga
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Via Benzinga
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
From Summit Therapeutics Inc.
Via Business Wire
Day Trading During A Slow Holiday Week
Via Talk Markets
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Via Talk Markets
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
From Summit Therapeutics Inc.
Via Business Wire
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
From Summit Therapeutics Inc.
Via Business Wire
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Zscaler Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Marvell Technology Posts Weak Q1 Results, Joins MongoDB, Dell Technologies And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Summit Therapeutics Inc.
Via Business Wire
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
From Summit Therapeutics Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Summit Therapeutics Stock Is Sinking Today
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.